{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:53Z","timestamp":1786119353391,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1097\/iae.0b013e3181b773e1","type":"journal-article","created":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T03:23:13Z","timestamp":1254885793000},"page":"1227-1234","source":"Crossref","is-referenced-by-count":11,"title":["INTRAVITREAL BEVACIZUMAB FOR TREATMENT-NA\u00cfVE PATIENTS WITH SUBFOVEAL OCCULT CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION"],"prefix":"10.1097","volume":"29","author":[{"given":"CIRO","family":"COSTAGLIOLA","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARY","family":"ROMANO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHELE DELLA","family":"CORTE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RAFFAELE","family":"PERROTTA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MASSIMO","family":"MENZIONE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHELE","family":"RINALDI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FRANCESCO","family":"SEMERARO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FRANCESCO","family":"PARMEGGIANI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210130","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.ophtha.2004.11.040","article-title":"14-Year incidence, progression, and visual morbidity of age-related maculopathy: the Copenhagen City Eye Study.","volume":"112","author":"Buch","year":"2005","journal-title":"Ophthalmology"},{"key":"R2-3-20210130","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ophtha.2006.10.040","article-title":"Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study.","volume":"114","author":"Klein","year":"2007","journal-title":"Ophthalmology"},{"key":"R3-3-20210130","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ajo.2006.05.061","article-title":"Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases.","volume":"142","author":"Kaiser","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R4-3-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2006.09.002","article-title":"Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy.","volume":"26","author":"Zhang","year":"2007","journal-title":"Prog Retin Eye Res"},{"key":"R5-3-20210130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00006982-200502000-00002","article-title":"Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.","volume":"25","year":"2005","journal-title":"Retina"},{"key":"R6-3-20210130","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R7-3-20210130","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/bjo.2005.082255","article-title":"Evolving European guidance on the medical management of neovascular age related macular degeneration.","volume":"90","author":"Chakravarthy","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R8-3-20210130","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization\u2014verteporfin in photodynamic therapy report 2.","volume":"131","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R9-3-20210130","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/archopht.122.4.453","article-title":"Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.","volume":"122","author":"Axer-Siegel","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R10-3-20210130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","article-title":"Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R11-3-20210130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R12-3-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2006.02.037","article-title":"Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.","volume":"142","author":"Bashshur","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R13-3-20210130","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","article-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"R14-3-20210130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00417-006-0466-4","article-title":"Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.","volume":"245","author":"Lazic","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R15-3-20210130","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00417-006-0471-7","article-title":"Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration.","volume":"245","author":"Aisenbrey","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R16-3-20210130","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1600-0420.2007.01113.x","article-title":"A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.","volume":"86","author":"Algvere","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R17-3-20210130","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1755-3768.2008.01262.x","article-title":"Intravitreal bevacizumab for treatment-na\u00efve subfoveal occult choroidal neovascularization in age-related macular degeneration.","volume":"87","author":"Furino","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"R18-3-20210130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":"Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).","volume":"246","author":"Wu","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R19-3-20210130","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/IAE.0b013e31817e100f","article-title":"Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease.","volume":"28","author":"Wong","year":"2008","journal-title":"Retina"},{"key":"R20-3-20210130","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1097\/IAE.0b013e3181803c2a","article-title":"Outcome of bevacizumab (Avastin) injection in patients with age-related macular degeneration and low visual acuity.","volume":"28","author":"Ehrlich","year":"2008","journal-title":"Retina"},{"key":"R21-3-20210130","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0039-6257(05)80092-X","article-title":"An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group.","volume":"39","author":"Bird","year":"1995","journal-title":"Surv Ophthalmol"},{"key":"R22-3-20210130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1600-0420.2005.00443.x","article-title":"Natural course of occult choroidal neovascularization in age-related macular degeneration: development of classic lesions in fluorescein angiography.","volume":"83","author":"Schneider","year":"2005","journal-title":"Acta Ophthalmol Scand"},{"key":"R23-3-20210130","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1167\/iovs.07-1654","article-title":"Coagulation gene predictors of photodynamic therapy for occult choroidal neovascularization in age-related macular degeneration.","volume":"49","author":"Parmeggiani","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R24-3-20210130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/14622416.10.1.81","article-title":"Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration.","volume":"10","author":"Parmeggiani","year":"2009","journal-title":"Pharmacogenomics"},{"key":"R25-3-20210130","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.ophtha.2005.09.007","article-title":"Time course and morphology of vascular effects associated with photodynamic therapy.","volume":"112","author":"Schmidt-Erfurth","year":"2005","journal-title":"Ophthalmology"},{"key":"R26-3-20210130","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/jama.293.12.1509","article-title":"Inhibitors of ocular neovascularization promises and potential problems.","volume":"293","author":"Van Wijngaarden","year":"2005","journal-title":"JAMA"},{"key":"R27-3-20210130","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/019262339902700507","article-title":"Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full length and Fab antibodies in rhesus monkeys following intravitreal administration.","volume":"27","author":"Mordenti","year":"1999","journal-title":"Toxicol Pathol"},{"key":"R28-3-20210130","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","article-title":"Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).","volume":"26","author":"Shahar","year":"2006","journal-title":"Retina"},{"key":"R29-3-20210130","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/archopht.121.9.1253","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment\u2014TAP and VIP report No. 2.","volume":"121","author":"Barbazetto","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R30-3-20210130","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IAE.0b013e31813ffe90","article-title":"12-Month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration.","volume":"28","author":"Incorvaia","year":"2008","journal-title":"Retina"},{"key":"R31-3-20210130","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.ophtha.2007.04.030","article-title":"Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.","volume":"114","author":"Kaiser","year":"2007","journal-title":"Ophthalmology"},{"key":"R32-3-20210130","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1136\/bjo.2007.116616","article-title":"Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.","volume":"91","author":"Raftery","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R33-3-20210130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2165\/00019053-200826010-00006","article-title":"Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.","volume":"26","author":"Cruess","year":"2008","journal-title":"Pharmacoeconomics"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0b013e3181b773e1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:05:55Z","timestamp":1786039555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006982-200910000-00003"}},"subtitle":["A 12-Month Follow-Up Study"],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e3181b773e1","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}